Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05652907 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of FSD201 for the Treatment of Chronic Pain Associated With Idiopathic MCAS (MCAD)
A Phase 2 study, sponsored by Quantum Biopharma.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT05652907 is a Phase 2 study that was terminated before completion, run by Quantum Biopharma. The registered enrollment target is 2 participants.
The verdict
NCT05652907, a Phase 2 study, was terminated before completion, sponsored by Quantum Biopharma.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
This study will determine if FSD201 reduces the average daily 24-hour recall pain intensity after 28 and 56 days of treatment in adults with chronic widespread musculoskeletal nociplastic pain.
Interventions
- DRUG Placebo
- DRUG FSD201
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2023-01-19 |
| Est. Completion | 2023-05-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05652907
The ClinicalTrials.gov registry entry for NCT05652907 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Quantum Biopharma, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05652907 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05652907 about?
NCT05652907 is a clinical study titled "Safety and Efficacy of FSD201 for the Treatment of Chronic Pain Associated With Idiopathic MCAS (MCAD)". This study will determine if FSD201 reduces the average daily 24-hour recall pain intensity after 28 and 56 days of treatment in adults with chronic widespread musculoskeletal nociplastic pain.
What is the current status of trial NCT05652907?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2023-01-19. Estimated completion is 2023-05-24.
What interventions are being tested in trial NCT05652907?
The interventions under investigation include: Placebo (DRUG), FSD201 (DRUG).
Who is sponsoring clinical trial NCT05652907?
This trial is sponsored by Quantum Biopharma, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.